The 'Dispatched' Week in Review Podcast - 4 October

This is a preview of subscriber content

Subscribe now to continue reading.

A significant structural change in the PBS, which the Government attempted to blunt with 60-day dispensed quantities, is arguably the main growth driver in spending on the program. We discuss the change, which along with others, represents a major reversal in a decades-long approach to medicines access. …

Subscribe now to continue reading.

The 'Dispatched' Week in Review Podcast - 4 October

This is a preview of subscriber content

Latest Video

Most Read

Lilly's Mounjaro will not be listed on PBS because of 'unrealistic' recommendation

Quarter of a century after the case that led to the PBAC's unaccountability loop

Outcomes deliver disappointment for vaccine advocates but progress on paediatric access to biologics

This makes it twice in two weeks, so at what point do we accept there's a problem?

'Let me once again explain why we must close the gap for people with cystic fibrosis–related diabetes'

New Stories

Moderna taps Salesforce to unify global commercial operations

How do we know the HTA institution loves patients? Because they use a love heart emoji

Australian company secures capital raise to advance amsulostat trials and strengthen pipeline

Australia urged to strengthen sunscreen literacy and label clarity

'Let me once again explain why we must close the gap for people with cystic fibrosis–related diabetes'

We need to say it again, just in case, that this advice is about ministerial choices and not conditions

Families welcome cancer drug progress but remain cautious over timely access

Sign In

The 'Dispatched' Week in Review Podcast - 4 October

This is a preview of subscriber content

Latest Video

Most Read

Lilly's Mounjaro will not be listed on PBS because of 'unrealistic' recommendation

Quarter of a century after the case that led to the PBAC's unaccountability loop

Outcomes deliver disappointment for vaccine advocates but progress on paediatric access to biologics

This makes it twice in two weeks, so at what point do we accept there's a problem?

'Let me once again explain why we must close the gap for people with cystic fibrosis–related diabetes'

Follow Us

New Stories

Moderna taps Salesforce to unify global commercial operations

How do we know the HTA institution loves patients? Because they use a love heart emoji

Australian company secures capital raise to advance amsulostat trials and strengthen pipeline

Australia urged to strengthen sunscreen literacy and label clarity

'Let me once again explain why we must close the gap for people with cystic fibrosis–related diabetes'

We need to say it again, just in case, that this advice is about ministerial choices and not conditions

Families welcome cancer drug progress but remain cautious over timely access